390405-95-5Relevant academic research and scientific papers
Synthesis of optically active α-bromohydrins via reduction of α-bromoacetophenone analogues catalyzed by an isolated carbonyl reductase
Ren, Jie,Dong, Wenyue,Yu, Benqing,Wu, Qiaqing,Zhu, Dunming
, p. 497 - 500 (2012)
Enantiomerically pure (S)-α-bromohydrins were prepared by the reduction of α-bromoacetophenone analogues catalyzed by an isolated carbonyl reductase from Candida magnolia with high yield and excellent enantiomeric excess when methyl tert-butyl ether was employed as the co-solvent, while avoiding the formation of by-products. This provides a new approach to access these chiral α-bromohydrins which are of pharmaceutical importance.
An imidazolium-modified chiral rhodium/diamine-functionalized periodic mesoporous organosilica for asymmetric transfer hydrogenation of α-haloketones and benzils in aqueous medium
Zhou, Feng,Hu, Xiaoying,Gao, Ming,Cheng, Tanyu,Liu, Guohua
, p. 5651 - 5657 (2016/10/21)
The use of a hydrophobic, imidazolium-functionalized periodic mesoporous organosilica for immobilization of chiral organometallic complexes as a heterogeneous catalyst is highly desirable as this catalyst can greatly promote an aqueous organic transformation due to its hydrophobic function and phase-transfer feature in an aqueous medium. Herein, by utilizing a three-component co-condensation strategy, we conveniently incorporate 1,2-bis(triethoxysilyl)ethane, (R,R)-4-((trimethoxysilyl)ethyl)phenylsulfonyl-1,2-diphenylethylene-diamine and 1,3-bis(3-(triethoxysilyl)propyl)-1H-imidazol-3-ium iodide within its silicate network, which is coordinated with (Cp?RhCl2)2, leading to an imidazolium-modified chiral rhodium/diamine-functionalized periodic mesoporous organosilica. A solid-state carbon spectrum discloses its well-defined chiral rhodium/diamine active species, and its X-ray diffraction; nitrogen adsorption-desorption measurement and transmission electron microscopy images reveal its ordered dimensional-hexagonal mesostructure. As a bifunctional heterogeneous catalyst, this periodic mesoporous organosilica significantly boosts asymmetric transfer hydrogenation of α-haloketones and benzils in water, where the hydrophobic periodic mesoporous organosilica, phase-transfer-featured imidazolium-functionality, and the confined chiral organorhodium catalytic nature are responsible for its catalytic performance. Furthermore, the catalyst can be recovered and recycled seven times without the loss of its catalytic activity, making it an attractive heterogeneous catalyst for asymmetric transfer hydrogenation in an environmentally friendly manner.
Asymmetric synthesis of β-adrenergic blockers through multistep one-pot transformations involving in situ chiral organocatalyst formation
Wei, Shengwei,Messerer, Regina,Tsogoeva, Svetlana B.
supporting information; scheme or table, p. 14380 - 14384 (2012/02/01)
Two birds one stone: A new atom-economical one-pot approach to enantioselective chiral drug synthesis, involving in situ multistep organocatalyst formation and the application of the reaction for multistep sequential synthesis of β-adrenergic blockers is disclosed (see scheme).
Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists
Barrow, James C,Nantermet, Philippe G,Selnick, Harold G,Glass, Kristen L,Ngo, Phung L,Young, Mary Beth,Pellicore, Janetta M,Breslin, Michael J,Hutchinson, John H,Freidinger, Roger M,Condra, Cindra,Karczewski, Jerzy,Bednar, Rodney A,Gaul, Stanley L,Stern, Andrew,Gould, Robert,Connolly, Thomas M
, p. 2691 - 2696 (2007/10/03)
Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets.
